# LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

> **NCT04703153** · — · UNKNOWN · sponsor: **Lucence Health Inc.** · enrollment: 151 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04703153
- **Lead sponsor:** Lucence Health Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-05
- **Primary completion:** 2022-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2023-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04703153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04703153, "LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04703153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*